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Dr Stephen E. Fremes (Toronto, Ontario, Canada). I do not
have any personal conflicts of interest to declare.
This study reports on a 5-year patency of RA, free RITA, and SV
grafts to non-LAD targets. The study is remarkable in that more
than 600 patients were recruited for a surgical trial, all from a single
center. The study has been performed with great rigor, with few
protocol violations or crossovers, with excellent follow-up, and
with a high rate of late angiography. Putting this study into context,
the study comes from a center with a long history in angiographic
and clinical outcomes of coronary surgery, as well as the influence
of arterial conduits on patency.
Again, this study is, in reality, two separate trials, one comparing
the free RITA with the RA in younger patients and the second com-
paring RAs with the SV in older patients. The former study is truly
unique and to my knowledge is the first and only randomized con-
trolled trial comparing a free RITA and an RA. I would like to em-The Journal of Thoracic and Cphasize, however, that the authors are reporting 5-year results, and
it should be emphasized again that according to protocol, the angio-
graphic follow-up of the study is weighted toward the sixth to tenth
postoperative years. I have a few questions.
First, the manuscript says that the primary analysis was per-
formed according to a treatment received rather than an intention-
to-treat basis. Why would you do that when it is more likely
to introduce bias in terms of your results?
Dr Hayward. Thank you for your question, Dr Fremes. We had
a lot of discussions about whether the analysis should be by inten-
tion to treat. We reported last year the clinical outcome data, which,
as in any clinical trial, were analyzed by intention to treat, and we
therefore initially thought that we should follow that and report the
patency by intention to treat. However, it seemed a little curious to
report the patency of what we know to be an SV to a given target,
for example, as if it were an RA, as intended. The conduit is known,
the target is known, and if the crossover was for a legitimate reason,
its patency is a fact, related presumably to the conduit used, what-
ever was planned. The trial is intended as a pragmatic trial to guide
surgeons. The surgeon wants to know, ‘‘If I place a saphenous vein
to this marginal, what will the patency be?’’, rather than ‘‘What
would the patency be if I planned to perform a radial, but didn’t?’’
So after some discussion we decided to follow the conduit used.
However, I agree that you can argue it either way. We did in fact
perform the analysis by intention to treat as well just for a statistical
cross-check, and actually it does not influence the results one iota.
But I agree that you could make this criticism of our decision.
Dr Fremes. I think if there are a lot of crossovers, then it is very
difficult to know what to do, but you had very few crossovers or
protocol violations.
Have you identified any patient or vessel predictors of graft fail-
ure overall or for the different types of grafts?
Dr Hayward. In this subset, no, we have not, because we have
not asked the question.We decided that because the number of graft
failures thus far has been relatively small, we would be playing with
such small numbers that it would be meaningless. Thus we have not
yet done the sort of analysis that you published for your cohort last
year. That will come when we have the full 10-year data.
Dr Fremes. I suspect that several patients have likely undergone
serial angiography in your study. Do you have any insights that
may be relevant from these patients?
Dr Hayward. From an article we published last year, we did re-
port a small number of patients that have had serial angiograms.
They were patients who had the protocol-directed angiogram and
then opted for the 5-year angiogram as well, and there were only
two changes, or two failures, in cases that had previously been re-
ported. Therefore, there was a 99% correlation. The groups that I
have just presented today contain only the protocol-directed angio-
grams. We took the last angiogram as the end point, effectively.
The moment a graft failed, it remains failed whatever a future an-
giogram may suggest, or if for some reason they had two angio-
grams and both have shown the graft as patent, we have taken
the longer follow-up, for obvious reasons.
Dr Fremes. That is fine for the results, but were there any se-
quential findings that may give you some insights as to what might
happen if there is longer-term follow-up?
DrHayward.Not yet at this point, no. Not enough patients have
had two angiograms.ardiovascular Surgery c Volume 139, Number 1 65
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DDr Fremes. One of the surprising results was the patency of the
SV. The patients were recruited largely from the 1990s as opposed
to somemore recent studies, for example, the PREVENT IV, which
have shown much poorer results. Can you speculate as to the pos-
sible reasons for this disparity?
Dr Hayward. I think ultimately the two factors have been sur-
gical technique and secondary prevention. I think secondary pre-
vention has been absolutely rigorous in that all patients have
been monitored by their hospital cardiologist, and the standard of
practice is extremely high in Australia. I agree that some of the pa-
tients were operated on at a time before with what we might regard
as the latest preventative strategies, but all the patients received ap-
propriate medications from surgery onward.
More important, though, is the surgical technique. The rigor with
which high-quality conduit is selected in Melbourne is very signif-
icant, in my opinion, and the delicacy and respect with which it is
handled is also striking. Because there is such concern about the
quality, often large amounts of conduit are harvested and only
a smaller segment used. I think it is that selectivity that has made
the difference here.
Dr Fremes. I have one final question, and you have alluded to
this a bit already: were there clinical events attributable to study
graft failure and how did they compare between the different grafts?
Dr Hayward. We do know the clinical events and published
these last year, and we do know the patients with the study graft
failures. In the 10-year results we are going to correlate those
two. But in the current patency data we did not attempt to link
the patients from the two presentations, because at the moment
there have only been clinical events in about 10% of patients,
and there are only a small number of failed grafts. Thus there really
are not enough to draw any conclusions at this time. I have delib-
erately not done that. The data are there, but I think we should
wait until we have more graft failures.
Dr Thomas Z. Lajos (Greenwood, SC). I have no conflicts of
interest. I would like to congratulate the authors for this very excel-
lent study. I would like to make a comment and a question.
We investigated veins, reverse veins, with valves and without
valves, 10 years ago, and we found that if you take the best quality
veins on both sides, the longer patency is present in those that have
no valves. So it is a valveless vein. Their patency is about the same
as you have shown, and we found the same thing; with the veins,
when the follow-up starts to decrease, patency is in the end of 9
to 10 years. The valves in the veins create a dilatation, they create
turbulence, and they may create emboli and thrombus inside. Did
you discard those veins or you did you have a chance to discard
those veins that had valves versus no valves?
Dr Hayward. Veins were not necessarily discarded per se be-
cause they had valves, but because of the practice of selecting the
very best conduit. Where possible, lengths are trimmed between
the valves. So as far as possible we would have valveless segments
of vein. That, of course, is not achievable in all patients. But I agree
that no doubt the turbulence at those points is a major factor. Some-
times dilatations or outpouchings can be flattened off with a large
clip to try to make a smoother profile, but that does not remove
the disturbance of flow imposed by a valve. I would say that valves
are avoided where possible, but I would not say that this is a series
of valveless veins. That would be misleading. However, I certainly
agree with your conclusions.66 The Journal of Thoracic and Cardiovascular SurgeDr Georg Lutter (Kiel, Germany). Congratulations for your
good patency rate of your RA. Can you give us a little insight of
whether you applied some vasodilating substances to your RAs?
A second question might be whether you dissected them. Did
you take the fascia, the small thin layer of the fascia off, or did
you leave the conduit in place as you took it out from the lower
arm?
DrHayward. The RAs in our unit and by other surgeons inMel-
bourne are harvested by a very standardized technique that the se-
nior surgeons locally developed. One of the important design
features of the trial was that they standardized everything that
they could with the conduits. The RA is taken as a pedicle, a rela-
tively narrow pedicle, but the artery is never touched at all, and the
only manipulation is of the fascia. The artery is divided early on dis-
tally and then retrogradely injected with a solution of papaverine
dilated in blood and Ringer lactate 50/50, and that same solution
is used for the veins as well. The graft is then clipped off at the distal
end and the dissection of the pedicle is then completed while the
graft is allowed to dilate with normal blood pressure; only at the
last minute is it removed from the proximal end. Then it is placed
in a bath of papaverine and blood and Ringer lactate. All the con-
duit types were treated in the same manner.
Dr Thoralf Sundt (Rochester, Minn). I suspect I know the an-
swer to this question, but there has been speculation that the poor
vein graft patency in the PREVENT IV trial was due to endoscopic
harvest. Were any of these veins harvested endoscopically, and
could you make a comment about the potential impact of that inno-
vation on graft patency?
DrHayward.All the veins were harvested by an open technique
here. I think that the delicacy with which the conduit is handled in
Melbourne would make an endoscopic approach to this very diffi-
cult. Many of us who have had any experience, and in my case rel-
atively limited experience, with endoscopic harvest have been
uncomfortable with the amount of traction I or we have placed
on the vessels. Endothelial integrity is absolutely key to these pa-
tency results, and this integrity might have been threatened by an
endoscopic method. These veins were all taken in a shamelessly
open no-touch manner.
DrCharles C. Canver (Riyadh, Saudi Arabia).Congratulations
on your outstanding work. I think you, Dr Buxton, and your other
group members have contributed immensely to our understanding
of the clinical use of the RA as a conduit. Most of the experienced
surgeons sensed the need for the RA during coronary artery bypass
grafting, but most were very skeptical owing to its vasospastic na-
ture. Accordingly, it is gratifying to see that your results support
that the RA is probably the second best arterial conduit. I have
a couple of questions for you.
First, have you ever used the RA as a sequential graft or have you
simply used the RA to a single coronary target? Second, if the pa-
tients had insulin-dependent diabetes, did you validate the quality
of the in situ RA? Last, have you used any preservative solutions
to prevent RA spasm just before its use in the operating room,
that is, a mixture of papaverine, nitroglycerin, diltiazem, or what-
ever? In addition, did you use any perioperative intravenous vaso-
dilators, that is, diltiazem, nitroglycerin, or milrinone?
Dr Hayward. Thank you. I will take your questions in reverse
order. On the table, as I said, after harvesting, the conduit is in a pa-
paverine–blood–Ringer lactate bath and is kept flushed with thisry c January 2010
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Dsolution. In terms of intravenous agents, at completion of the pro-
cedure the patients at Austin are given low-dose milnirone as an ar-
terial graft dilator, and that is run for about 24 hours unless there is
a reason to discontinue it, such as low systemic vascular resistance
state or excessive cardiac output. The use and dose of the milnirone
is entirely vasodilating in its intent rather than inotropic. I think that
is an important factor in the treatment of arterial grafts in this series.
A substantial number of the patients did have diabetes. Type II
diabetes was predominant, although type I diabetes was present
in about 15% of those with diabetes. The patients were all assessed
by a preoperative Allen test, and then intraoperatively, before use,
the RA was inspected and palpated for calcification. After harvest-
ing, if the internal lumen showed evidence of atheroma or calcifica-
tion, then it was discarded. There was no Doppler study, if that isThe Journal of Thoracic and Cwhat you were referring to, but a fairly rigorous visual inspection
and palpation were made of the conduit.
Your final question had to do with sequential grafts. All of these
are grafts with single distal anastomoses. There were a few patients
who received sequential grafts, but they were then eliminated from
the study, as shown on the flow diagram. We are not opposed to se-
quential grafting, and in fact, a proportion of the LITAs were se-
quentially grafted. I think there is a growing body of opinion that
if you double the territory of runoff for the graft, you may in fact
improve its patency, but that could bias your patency data. For
the purposes of this trial, to keep it simple and reproducible, the ran-
domized or study conduit had to be used with one distal end, and if
used sequentially with a larger bed of runoff, it was eliminated from
the study.ardiovascular Surgery c Volume 139, Number 1 67
